Poultry vaccine is a biological preparation that provides active acquired immunity to prevent any particular disease. Poultry vaccines have the capability to trigger the immune system by producing antibodies, which in turn, fight against organisms such as E. coli, Salmonella, and Mycoplasma gallisepticum (MG) from causing diseases.
The size of the global market for poultry vaccines is expected to reach US$ 2,845.00 million by 2028, expanding at a compound annual growth rate (CAGR) of 6.4%.
The poultry population is growing due to abundant feed supplies and sufficient demand globally. The emergence of innovation in poultry production such as robotics & automation (e.g. Gohbot, ChickenBoy), big data and artificial intelligence (e.g. Poultry System Simulation Model, SDSS Multitier Statistical Process Control), and nanotechnology for virus detection bolsters the poultry population. The demand for animal protein is expanding, which in turn pushes the need for production of poultry related food products. There is an increase in poultry meat consumption in developing countries as well, in which the broiler products dominate the international poultry trade. The adoption of poultry vaccines is increasing due to rising concerns about food safety, bacterial resistance, and animal welfare where the focus of poultry health center has switched to prevention than treatment. This transformation towards disease prevention has led to widespread adoption of vaccines to alleviate the impact of infectious diseases. Poultry vaccines have, had and continue to have, a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing zoonotic infections. Poultry vaccination programs are based on various factors such as biosecurity level, production type, pattern of local diseases, maternal immunity status, vaccines availability, costs and potential losses and the duration of immunity effect lasts longer and provides protection against infectious diseases such as avian Influenza, Newcastle disease, Marek's Disease and infectious bursal disease (Gumboro disease). Administration of vaccines through various routes such as in vivo, intramuscular, subcutaneous, ocular, oral, and nasal and are also applied to different areas of the egg such as the allantoic sac, amniotic fluid, body of embryo, air cell, and yolk sac.
Emergence of next-generation vaccines intensify adoption of poultry vaccines market:
The development of next-generation solutions such as vaccination in the hatchery, which have the potential to provide lifelong protection against different type of diseases is also a promising prospect in the industry. Vaccination in the hatchery includes administration of the vaccines either by injection (‘in-ovo’ or subcutaneous routes) or local application (spray or eye drop). Earlier maternal antibodies were transferred from birds to their offspring to protect them from diseases but vaccination in the hatchery provides better protection, because there are less chances for error and has a better safety profile, with more efficiency and convenience than having to vaccinate birds on a farm. Hatchery vaccination is affordable and most accepted, which will flourish the poultry vaccines market. Emerging innovations and technologies are making vaccines market to become more efficient and playing an even greater role in disease prevention. Additionally, at the backdrop of rising prevalence of zoonotic diseases globally, innovative vaccine development as a whole is gaining center stage prominence.
Avian influenza disease remain most prominent
The prevalence of avian influenza is visibly prominent across all the countries in the world such as United States, Asia, and Europe. It is a disease caused by infection with avian (bird) influenza (flu) Type A viruses which occur naturally within wild aquatic birds worldwide and can infect domestic poultry and animal species. Avian influenza is transmitted to human beings by direct contact and the intensity of the disease can vary from mild to severe. The World Organization for Animal Health has set certain standards for the vaccine approval for avian influenza. Avian influenza vaccine is given to imbibe the protection against hemagglutinin (HA) protein. Companies are actively involved in manufacturing new vaccines as preventive measures. Growing R&D activities, particularly in this field of vaccination, to curb various outbreaks in the aforementioned diseases. The disease is associated with high risk; hence, the regulatory bodies in poultry healthcare are now hastening the process of approval for various vaccines in the respective space.
North America is expected to dominate the market
North America is dominating the poultry vaccines market due to factors such as growing consumer awareness regarding food safety, increasing prevalence of zoonotic diseases associated with poultry, and the increase in consumption of poultry-derived products. Moreover, there is an increase in the production of eggs and hen and the poultry inventories in North America, as per the statistics published by the UNFAO. The CVB (Center for Veterinary Biologics) grants establishment and product license to animal health companies, to manufacture and sell veterinary biologics. In North America, innovation in vaccines development include the development of non-replicating recombinant antigen vaccines, live vector vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines.
Key Market Players
- Merck & Co. Inc.
- Ceva Santé Animale
- Boehringer Ingelheim International GmbH
- Venky’s Limited
- Ringpu Biology
- Phibro Animal Health Corporation
poultry vaccines market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||US$ 2,845.00 million|
|Growth Rate||CAGR of 6.4 % during 2021-2028|
|Segment Covered||Based on type, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Boehringer Ingelheim International GmbH, Zoetis Inc., Ceva Santé Animale, BIOVAC, Phibro Animal Health CorporationHester Biosciences Limited, Venky's India, Dechra Pharmaceuticals PLC, Elanco, Merck Animal Health|
Following is a detailed snapshot of most prominent segments in global poultry vaccines market.
Segmentation by Disease: Global Poultry Vaccines Market
- Avian Influenza
- Newcastle disease
- Marek's Disease
- Infectious Bronchitis
Segmentation by technology: Global Poultry Vaccines Market
- Recombinant Vaccines
- Inactivated Vaccines
- Live Attenuated Vaccines (LAV)
- DNA Vaccines
Segmentation by Application: Global Poultry Vaccines Market
Regional Segmentation: Global Poultry Vaccines Market
- North America
- Rest of the World
Key Market Movements
- Large scale prevalence of zoonotic diseases corresponding to the growing poultry population, are driving product demand in the market
- Increasing poultry inventories and improvement in livestock productivity fuels growth
- Rising government initiatives for food safety pave way for further growth opportunities
- Increasing awareness among veterinary practitioners about animal vaccination bolsters market
- Next- generation vaccines and innovations likely to flourish the market
Key Questions Answered
- Market valuation in terms of value and volume of the global poultry vaccines market
- through the forecast span, 2019-25
- Comprehensive market evaluation across major regions based on market segmentation
- A thorough rundown on market dynamics such as drivers, threats, challenges, and opportunities
- A clear analytical review of competition spectrum, highlighting industry forerunners, company as well as product portfolios
- Major highlights on winning marketing strategies adopted by leading players